TransCode Therapeutics Inc. Common Stock (RNAZ)
Stock · NASDAQ · Health Care
$1.7as of 10/16/2026
Price chart
Active signals
RNAZ Signal Track Record
How signals performed across all stocks →What RNAZ's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakdown | 23 | -28.5% | 22% | July 28, 2026 |
| Bollinger Band Breakout | 18 | -21.2% | 33% | October 9, 2026 |
| Volume Spike | 11 | -10.1% | 27% | September 21, 2026 |
| 200-Day Moving Average TouchActive now | 3 | -10.0% | 0% | July 10, 2026 |
| Any 20-session window (baseline) | -16.5% | 29% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About RNAZ
TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in v…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 12
Fundamentals
- 1-day range
- $1.71$1.9
- Market cap
- $4.52M
- P/E (trailing)
- —
- P/E (forward)
- -3.02
- EPS (trailing)
- $-47.00
- Dividend yield
- —
- Beta
- 1.29
- Avg. volume
- 51.7K
TransCode Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- RNAZTransCode Therapeutics Inc. Common Stock$1.7▼ 5.56%Market cap $4.52MP/E —$1.52$15.94
- DRMADermata Therapeutics Inc. Common Stock$0.86▼ 5.49%Market cap $4.46MP/E —$0.6032$4.66
- JAGXJaguar Health Inc. Common Stock$3.53▼ 23.20%Market cap $4.61MP/E —$2.35$1,268
- REVBRevelation Biosciences Inc. Common Stock$0.485▼ 36.35%Market cap $4.38MP/E 0.04$0.71$5.8
- ELABPMGC Holdings Inc. Common Stock$2.77▼ 8.88%Market cap $4.34MP/E —$2.59$2,671
- PPCBPropanc Biopharma Inc. Common Stock$0.342▲ 0.15%Market cap $4.76MP/E —$0.365$47.5
- JUNSJupiter Neurosciences Inc. Common Stock$2.9▼ 7.48%Market cap $4.24MP/E —$2.25$135.75
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| RNAZ TransCode Therapeutics Inc. Common Stock | $4.52M | — | $1.7 | ▼ 5.56% | $1.52$15.94 |
| DRMA Dermata Therapeutics Inc. Common Stock | $4.46M | — | $0.86 | ▼ 5.49% | $0.6032$4.66 |
| JAGX Jaguar Health Inc. Common Stock | $4.61M | — | $3.53 | ▼ 23.20% | $2.35$1,268 |
| REVB Revelation Biosciences Inc. Common Stock | $4.38M | 0.04 | $0.485 | ▼ 36.35% | $0.71$5.8 |
| ELAB PMGC Holdings Inc. Common Stock | $4.34M | — | $2.77 | ▼ 8.88% | $2.59$2,671 |
| PPCB Propanc Biopharma Inc. Common Stock | $4.76M | — | $0.342 | ▲ 0.15% | $0.365$47.5 |
| JUNS Jupiter Neurosciences Inc. Common Stock | $4.24M | — | $2.9 | ▼ 7.48% | $2.25$135.75 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-UpYahoo · 9/28/2026
- TransCode Therapeutics Announces Updated Clinical Data From Phase 1a Clinical Trial Of TTX-MC138, Reinforcing Evidence Of Antitumor Activity In Heavily Pretreated Patients With Advanced Solid TumorsBenzinga · 9/28/2026
- TransCode Therapeutics Announces Patent Advancements in Australia and Japan Strengthening Global IP Position in RNA-Based Immuno-OncologyYahoo · 9/22/2026
- TransCode Therapeutics Announces Australia Acceptance Of Patent application, Japan's Issuance Of Notice Of Allowance For Its RNA-Based Therapeutic Platform TechnologiesBenzinga · 9/22/2026
- TransCode Therapeutics, Inc. (RNAZ) Discusses Advancing Multi-Platform Oncology Pipeline Targeting Metastatic Cancer TranscriptSeekingAlpha · 9/16/2026
- Join Today's Live Investor Webinar with TransCode TherapeuticsYahoo · 9/16/2026
Insider Activity
Insider Actions →- Fitzgerald Thomas A · September 9, 2026 · Grant185.0K
- DEFJ, LLC · August 3, 2026 · Conversion202
- DEFJ, LLC · August 3, 2026 · Conversion1.2K
- DEFJ, LLC · August 3, 2026 · Conversion2.02M
- DEFJ, LLC · August 3, 2026 · Conversion11.81M
Institutional Ownership
March 31, 2026
- Total shares held
- 27.9K
- Total value held
- $240.0K
- Institutional holders
- 7
- Unknown12.7K
- Unknown8.3K
- Unknown6.5K
- Unknown228
- Unknown55
- Unknown12
- Unknown8
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
TransCode Reports Phase 1a Data for TTX-MC138
TransCode Therapeutics released updated results from its Phase 1a trial of TTX-MC138. The company reported continued disease stabilization and extended treatment duration in patients with advanced solid tumors. These findings add to the clinical evidence for the drug in heavily pretreated patients.
TransCode Reports Phase 1a Data for TTX-MC138. TransCode Therapeutics released updated results from its Phase 1a trial of TTX-MC138. The company reported continued disease stabilization and extended treatment duration in patients with advanced solid tumors. These findings add to the clinical evidence for the drug in heavily pretreated patients.